Crossmark

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

Crossref DOI link: https://doi.org/10.1016/j.annonc.2023.05.008

Published Print: 2023-08

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Tarantino, P.

Viale, G.

Press, M.F.

Hu, X.

Penault-Llorca, F.

Bardia, A.

Batistatou, A.

Burstein, H.J.

Carey, L.A.

Cortes, J.

Denkert, C.

Diéras, V.

Jacot, W.

Koutras, A.K.

Lebeau, A.

Loibl, S.

Modi, S.

Mosele, M.F.

Provenzano, E.

Pruneri, G.

Reis-Filho, J.S.

Rojo, F.

Salgado, R.

Schmid, P.

Schnitt, S.J.

Tolaney, S.M.

Trapani, D.

Vincent-Salomon, A.

Wolff, A.C.

Pentheroudakis, G.

André, F.

Curigliano, G.
Funding

Funding for this research was provided by:

AstraZeneca

Roche
License Information

Text and Data Mining valid from 2023-08-01

Text and Data Mining valid from 2023-08-01

Version of Record valid from 2024-08-01
More Information

This article is maintained by: Elsevier

Article Title: ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

Journal Title: Annals of Oncology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.annonc.2023.05.008

Content Type: article

Copyright: © 2023 European Society for Medical Oncology. Published by Elsevier Ltd.